Please assess the completion status of the following clinical trial:

Trial Title: Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Age \>= 18 years~* Histologically confirmed diagnosis of squamous cell carcinoma of the penis~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.~* Measurable disease criteria according to RECIST criteria (version 1.1)~* Progressive disease after treatment with cisplatin or carboplatin based chemotherapy.~* Archived tumor tissue must be provided for all subjects for biomarker analysis before and/or during treatment with investigational product.~* Adequate organ system function - Haemoglobin \>= 9.0 gr/dl (5.6 mmol/L) and stable in the previous 4 weeks to start study treatment - Neutrophils \>= 1.5 x 10\*9/L - Platelets \>= 100 x 10\*9/L - Total bilirubin \<= 1.5 x UNL - AST/SGOT and ALT/SGPT \<= 2.5 x UNL - serum creatinine \<= 1.5 mg/dL - Urine protein to creatinine ratio \< 1.~* Normal coagulation tests: - Prothrombin time (PT) or international normalized ratio (INR) \<= 1.2 X ULN - Activated partial thromboplastin time (aPTT) \<= 1.2 X ULN 10. Are able to swallow and retain oral tablets~Exclusion Criteria:~* Prior malignancy.~* Central nervous system metastases at baseline, with the exception of those subjects who have previously-treated CNS metastases (surgery ± radiotherapy, radiosurgery, or gamma knife) and who meet both of the following criteria: a) are asymptomatic and b) have no requirement for steroids or enzyme-inducing anticonvulsants~* Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding.~* Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product.~* Corrected QT interval (QTc) \> 480 ms~* History of any one or more of the following cardiovascular conditions within the past 6 months: - Cardiac angioplasty or stenting - Myocardial infarction - Unstable angina - Coronary artery bypass graft surgery - Symptomatic peripheral vascular disease - Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA)~* Poorly controlled hypertension \[defined as systolic blood pressure (SBP) of \>= 140 mmHg or diastolic blood pressure (DBP) of \>= 90 mmHg\].~* History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.~* Evidence of active bleeding or bleeding diathesis.~* Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that increase the risk of pulmonary hemorrhage~* Recent hemoptysis (\>= 1/2 teaspoon \[2.5 mL\]) of red blood within 8 weeks before first dose of study drug).~* Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subjects safety, provision of informed consent, or compliance to study procedures.~* Unable or unwilling to discontinue use of prohibited medications 14 days prior to the first dose of study drug and for the duration of the study.~* Treatment with any of the following anti-cancer therapies: - radiation therapy, surgery or tumor embolization within 14 days prior to the first dose of pazopanib OR - chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days prior to the first dose of Pazopanib~* Administration of any non-oncologic investigational drug within 30 days prior to receiving the first dose of study treatment~* Any ongoing toxicity from prior anti-cancer therapy that is \>Grade 1 and/or that is progressing in severity, except alopecia.~* Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib or paclitaxel and/or excipients that contraindicates their participation.~* Previous taxane or/and antiVEGF treatment would not allow patient to participate in the study.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pazopanib plus weekly paclitaxel (Type: EXPERIMENTAL): Pazopanib 800mg /day continuously administered plus paclitaxel 65 mg/m2 in weekly administration, 3 administrations (D1, D8 and D15) every 4 weeks period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues